GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Description
Brief Summary
This phase I/II trial studies the side effects and the best dose of Akt inhibitor GSK2141795
(GSK2141795) when given together with dabrafenib and trametinib and to see how well they
work in treating patients with stage IIIC-IV cancer. Akt inhibitor GSK2141795, dabrafenib,
and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. Giving Akt inhibitor GSK2141795 with dabrafenib and trametinib may be a better
treatment for cancer.
Phase
N/AInclusion and Exclusion Criteria
Please contact Carryl Du Bois to learn more about the eligibility criteria for this trial. Please use the contact form on the right side.
Sites
Please contact Carryl Du Bois to learn more about where you can participate in this trial. Please use the contact form on the right side.
Presentado por
SC CTSI